{
    "clinical_study": {
        "@rank": "3282", 
        "arm_group": {
            "arm_group_label": "Experimental", 
            "arm_group_type": "Experimental", 
            "description": "Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly)."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of cisplatin plus intensity-modulated radiotherapy\n      (IMRT) based on FDG-PET/CT after induction chemotherapy (IC) for locally advanced head and\n      neck squamous cell carcinoma."
        }, 
        "brief_title": "Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients aged 18 years or over;\n\n          -  Histologically confirmed locally advanced (stage III and IV) head and neck squamous\n             cell carcinoma  (HNSCC);\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;\n\n          -  Signed written informed consent approved by the Lithuanian Bioethics Committee\n             (LBEC);\n\n        Exclusion Criteria:\n\n          -  Positive serum pregnancy test in women of childbearing potential or breastfeeding;\n\n          -  Presence of distant metastasis;\n\n          -  Second primary tumor;\n\n          -  History of other malignancy within the last 5 years;\n\n          -  Recurrent head and neck cancer;\n\n          -  Serious uncontrolled concomitant disease that would contraindicate the use of any\n             drugs use in this study as chemotherapy or radiotherapy;\n                                 ;\n\n          -  Inadequate organ function, evidenced by the following laboratory results:\n\n               1. Absolute neutrophil count <1,500 cells/mm3;\n\n               2. Platelet count <100,000 cells/mm3;\n\n               3. Hemoglobin <9 g/dL;\n\n               4. Total bilirubin greater than the upper limit of normal (ULN);\n\n               5. AST (SGOT) or ALT (SGPT) >1,5 x ULN;\n\n               6. Alkaline phosphatase levels >2,5 x the ULN;\n\n               7. Serum creatinine >2,0 mg/dl or 177 umol/l."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047201", 
            "org_study_id": "EHNCTE-1309"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental", 
                "description": "IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).", 
                "intervention_name": "IMRT", 
                "intervention_type": "Radiation", 
                "other_name": "intensity-modulated radiation theraphy"
            }, 
            {
                "arm_group_label": "Experimental", 
                "description": "Assessing tumor response using FDG-PET/CT.", 
                "intervention_name": "PET/CT", 
                "intervention_type": "Radiation", 
                "other_name": "Positron emission tomography-computed tomography"
            }, 
            {
                "arm_group_label": "Experimental", 
                "description": "75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere, Docefrez"
            }, 
            {
                "arm_group_label": "Experimental", 
                "description": "750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.", 
                "intervention_name": "Fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": "5-Fluorouracil, Adrucil"
            }, 
            {
                "arm_group_label": "Experimental", 
                "description": "75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Platinol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cisplatin", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Head and neck cancer", 
            "PET/CT", 
            "induction chemotherapy", 
            "IMRT"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "contact": {
                "email": "rektoratas@lsmuni.lt", 
                "last_name": "Remigijus Zaliunas, Professor", 
                "phone": "+37037327200"
            }, 
            "facility": {
                "address": {
                    "city": "Kaunas", 
                    "country": "Lithuania", 
                    "zip": "LT-44307"
                }, 
                "name": "Lithuanian University of Health Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Ilona Kulakiene, Professor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Severina Sediene, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Viktoras Rudzianskas, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Vita Simonyte, Resident", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Lithuania"
        }, 
        "number_of_arms": "1", 
        "official_title": "Assessing Tumor Response and IMRT Treatment Planning After Induction Chemotherapy Based on FDG-PET/CT for Locally Advanced Head and Neck Squamous Cell Carcinoma.", 
        "overall_contact": {
            "email": "kulakiene@dr.com", 
            "last_name": "Ilona Kulakiene, Professor", 
            "phone": "+37037787340"
        }, 
        "overall_official": {
            "affiliation": "Lithuanian University of Health Sciences", 
            "last_name": "Ilona Kulakiene, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Lithuania: Bioethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "12 months after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047201"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lithuanian University of Health Sciences", 
            "investigator_full_name": "Ilona Kulakiene", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the tumour metabolic response (complete metabolic response [CMR], partial metabolic response [PMR], stable metabolic disease [SMD] or progressive metabolic disease [PMD]) to induction chemotherapy (IC) as assessed by FDG-PET/CT performed at baseline and 2 weeks after IC.", 
                "measure": "Tumour metabolic response", 
                "safety_issue": "No", 
                "time_frame": "2 weeks after IC"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "12 months after treatment"
            }, 
            {
                "measure": "Locoregional control", 
                "safety_issue": "No", 
                "time_frame": "12 months after treatment"
            }, 
            {
                "description": "To evaluate the tumour anatomic response (complete response [CR], partial response [PR], stable disease [SD] or progressive disease [PD]) to induction chemotherapy (IC) as assessed by FDG-PET/CT performed at baseline and 2 weeks after IC.", 
                "measure": "Tumour anatomic response", 
                "safety_issue": "No", 
                "time_frame": "2 weeks after IC"
            }, 
            {
                "description": "To compare SUVmax and SUVav as assessed by FDG-PET/CT performed at baseline and 2 weeks after IC.", 
                "measure": "SUVmax and SUVav variations", 
                "safety_issue": "No", 
                "time_frame": "2 weeks after IC"
            }, 
            {
                "description": "To evaluate acute and late toxicity.", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "No", 
                "time_frame": "12 monhts from chemoradiotherapy"
            }, 
            {
                "description": "To evaluate the correlation of tumor metabolic response as assessed by FDG-PET/CT with the anatomic tumor response rate as assessed by CT.", 
                "measure": "Overall tumor metabolic and anatomic response correlation", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 2 weeks after IC"
            }, 
            {
                "description": "To evaluate the correlation of overall survival (OS), progression free survival (PFS), loco regional control (LRC) with metabolic tumor response, anatomic tumor response, baseline SUV and Human papillomavirus (HPV).", 
                "measure": "Overall survival (OS), progression free survival (PFS), loco regional control (LRC) correlation", 
                "safety_issue": "No", 
                "time_frame": "12 months after treatment"
            }
        ], 
        "source": "Lithuanian University of Health Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lithuanian University of Health Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}